--- title: "Assessing Novartis (SWX:NOVN) Valuation After Recent Share Weakness And Long Term Gains" type: "News" locale: "en" url: "https://longbridge.com/en/news/284816715.md" description: "Novartis (SWX:NOVN) has experienced recent share price fluctuations, with a 1-day return of 1.2% and a year-to-date return of 4.5%. Despite a 5.4% decline over the past month, the company reports strong financials with $56.6 billion in revenue and $13.5 billion in net income. Analysts suggest the stock is undervalued at CHF113.34 compared to a fair value of CHF120.89. The narrative highlights Novartis' potential in advanced therapies and operational efficiency, but warns of risks from drug exclusivity loss and pricing pressures. Investors are encouraged to explore further opportunities." datetime: "2026-04-30T17:55:44.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/284816715.md) - [en](https://longbridge.com/en/news/284816715.md) - [zh-HK](https://longbridge.com/zh-HK/news/284816715.md) --- # Assessing Novartis (SWX:NOVN) Valuation After Recent Share Weakness And Long Term Gains ## Recent share performance and business scale Novartis (SWX:NOVN) has drawn investor attention after a period where the share price shows a 1 day return of 1.2%, a past week return of a 1.9% decline, and a month return of a 5.4% decline. Over the past 3 months, the stock shows a 0.8% decline, while the year to date return stands at 4.5%. The 1 year total return is 24.5%, with 3 year and 5 year total returns of 43.1% and 82.4% respectively. The company reports revenue of $56.6b and net income of $13.5b, with annual revenue growth of 5.3% and net income growth of 9.7%. All revenue currently stems from the Innovative Medicines segment. See our latest analysis for Novartis. The recent 1 month share price return of a 5.4% decline contrasts with a 1 year total shareholder return of 24.5%. This points to fading short term momentum alongside a stronger multi year record. If that mix of near term weakness and longer term gains has you thinking about portfolio balance, it may be a good moment to scan for other ideas using our 124 healthcare AI stocks With Novartis shares at CHF113.34, sitting below an average analyst target of CHF121.67 and with an intrinsic value gap flagged, you have to ask: is this a genuine opportunity or is the market already baking in future growth? ## Most Popular Narrative: 6% Undervalued Against a last close of CHF113.34, the most followed narrative pegs Novartis at a fair value of about CHF120.89, leaving a modest valuation gap built on detailed long term forecasts and cash flow assumptions. > _Novartis' pipeline and regulatory progress in advanced therapies (including biologics, gene, and cell therapies) is presented as positioning the company to participate in emerging healthcare technologies, with the narrative suggesting this could influence future earnings and margin trends as new products launch._ > > _Operational efficiency gains from portfolio streamlining (for example, previous spin-offs and exiting non-core lines) and productivity changes are described as supporting core margin expansion and higher free cash flow in the narrative, which in turn is assumed to be available for reinvestment in R&D and shareholder returns over the long term._ _Read the complete narrative._ Curious what sits underneath that fair value line? Revenue pacing, margin shifts and future earnings all feed into a layered cash flow framework. The discount rate in the model is fixed, but the path to those future profits is defined by multiple assumptions. If you want to see which inputs have the greatest impact on the valuation, the full narrative lays them out step by step. The narrative relies on a specific combination of revenue growth, margin expansion and future P/E expectations, all brought back to today using a 3.914% discount rate. Analysts in that narrative estimate future earnings and share count, then solve for a price that aligns with those assumptions, treating CHF120.89 as the level where those forecasts and required returns intersect. **Result: Fair Value of CHF120.89 (UNDERVALUED)** Have a read of the narrative in full and understand what's behind the forecasts. However, be aware that the loss of exclusivity for key drugs and rising pricing pressure across major markets could quickly challenge the growth and margin assumptions behind that fair value. Find out about the key risks to this Novartis narrative. ## Next Steps Reading these mixed signals on value, risks and rewards, it makes sense to check the full picture yourself and not rely on a single narrative. If you want a quick way to see how the positives and negatives stack up side by side, start with the 4 key rewards and 1 important warning sign. ## Looking for more investment ideas? If Novartis has sharpened your thinking, do not stop here. A few minutes with targeted stock lists can surface opportunities that fit your goals before others notice. - Target reliable income by scanning companies built around steady cash returns using the 484 dividend fortresses. - Hunt for value by reviewing the screener containing 566 high quality undiscovered gems before they move onto everyone else's radar. - Prioritize resilience by focusing on companies in the 305 resilient stocks with low risk scores that show lower overall risk profiles. _This article by Simply Wall St is general in nature. **We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.** It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned._ ### Related Stocks - [NVS.US](https://longbridge.com/en/quote/NVS.US.md) - [NOT.DE](https://longbridge.com/en/quote/NOT.DE.md) - [XLV.US](https://longbridge.com/en/quote/XLV.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [IHE.US](https://longbridge.com/en/quote/IHE.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md) - [VHT.US](https://longbridge.com/en/quote/VHT.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) ## Related News & Research - [Relay's treatment shown to shrink vascular malformations in mid-stage trial](https://longbridge.com/en/news/286890329.md) - [](https://longbridge.com/en/news/286807703.md) - [REGENXBIO Advances Duchenne Gene Therapy Toward Accelerated Approval](https://longbridge.com/en/news/286443456.md) - [Editas Showcases Promising EDIT-401 Hyperlipidemia Preclinical Data](https://longbridge.com/en/news/286407513.md) - [Eton Pharmaceuticals Adds Another 2026 Launch As It Secures U.S. Rights To IMPAVIDO](https://longbridge.com/en/news/287025596.md)